Tekmira Pharmaceuticals share price shoots up 27pc after Ebola case confirmed in US
Shares in Canadian drugmaker Tekmira Pharmaceuticals soared in after-hours trading yesterday after the Centers for Disease Control and Prevention confirmed the first case of the Ebola virus on US soil.
After closing about two per cent up, shares jumped 27 per cent to $26.82 on heavy volume.
In August, the US Food and Drug Administration began easing barriers for the use of its Ebola treatment, TKM-Ebola, after successful trials.
The drug is being developed by Tekmira and the US Department of Defence and is in early-stage clinical trials.
Other pharmaceutical companies, including Sarepta Therapeutics, up seven per cent, and NewLink Genetics, up 14.5 per cent were also higher following the news.
All of these companies have been working on treatments for Ebola.